


Summary

The Charles River ion channel portfolio includes over 120 targets which have been organized into Channel Panels[®] based on current scientific findings, proving a useful tool in guiding early screening and selectivity profiling.



DISCOVERY

 Click to learn more

Ion Channel Families:

- Chloride (CLC-2)
- Calcium, voltage-gated (Cav2.1/ β_4 / $\alpha_2\delta_1$ and Cav3.2)
- Hyperpolarization-gated (HCN1 and HCN2)
- Ligand-gated (GABA_A ($\alpha_1\beta_2\gamma_2$, $\alpha_2\beta_2\gamma_2$, $\alpha_5\beta_2\gamma_2$) and NMDA (NR1/NR2A, NR1/NR2B))
- Potassium, calcium-activated (BK, IK, SK2 and SK3)
- Potassium, voltage-gated (Kv1.1, Kv4.2/KChiP2.2 and KCNQ (KCNQ2/3, KCNQ2/4 and KCNQ3/5))
- Sodium, voltage-gated (Nav1.1, Nav1.2, Nav1.3 and Nav1.6)

Need a custom version of this assay?

Visit [criver.com/pi-ds-ion-channel-profiling-assay](https://www.criver.com/pi-ds-ion-channel-profiling-assay)

Ion Channel Selectivity Profiling: Seizure/Convulsion

Our Seizure/Convulsion Channel Panel[®] includes ion channels expressed in the central nervous system (CNS) that have been linked to inherited forms of epilepsy.

Selectivity Profiling

Identification of a compound's target specificity and potential for off-target effects is a critical step in the drug discovery process and often includes assessments against specific target class families, critical safety targets or by therapeutic area. In addition to our [therapeutic area-specific Channel Panels[®]](#), we offer screening on a number of [electrophysiology platforms](#). When required, our scientists can design customized panels to meet a client's needs. As pioneers in the field of ion channels, we are able to provide expert consultation to facilitate interpretation of results.

Ion Channels and Seizures

[Ion channels](#) expressed in the CNS have been linked to inherited forms of epilepsy. Gain-of-function mutations in excitatory channels (e.g., voltage-gated sodium Nav1.1, Nav1.2 and Nav1.3, voltage-gated calcium Cav3.2, and hyperpolarization-gated HCN1 and HCN2 channels) have been shown to cause persistent, depolarizing currents leading to hyperexcitability that facilitates epileptic seizures and convulsions. Hyperexcitability also may result from loss-of-function mutations in inhibitory channels (e.g., voltage-gated potassium KCNQ, calcium-dependent potassium BK and ligand-gated chloride GABA_A). Adverse neurological events may be caused by drug side-effects that mimic mutation-induced alterations in channel function. Conversely, antiepileptic drugs can act as antagonists of excitatory channels or as agonists of inhibitory channels. Thus, the ion channels in our seizure-convulsion panel are potential therapeutic targets for treatment of hyper-excitability (e.g., seizure, [pain](#), [neurodegeneration](#), [anxiety](#), [migraine](#) and [psychosis](#)) as well as targets for adverse events.

EVERY STEP OF THE WAY